260 related articles for article (PubMed ID: 20498929)
1. [Nonsteroidal anti-inflammatory drugs: cardiovascular, cerebrovascular and renal effects].
Batlouni M
Arq Bras Cardiol; 2010 Apr; 94(4):556-63. PubMed ID: 20498929
[TBL] [Abstract][Full Text] [Related]
2. Use of nonsteroidal anti-inflammatory drugs in patients with cardiovascular disease: a cautionary tale.
Amer M; Bead VR; Bathon J; Blumenthal RS; Edwards DN
Cardiol Rev; 2010; 18(4):204-12. PubMed ID: 20539104
[TBL] [Abstract][Full Text] [Related]
3. Potential cardiovascular effects of COX-2 selective nonsteroidal antiinflammatory drugs.
Fowles RE
J Pain Palliat Care Pharmacother; 2003; 17(2):27-50. PubMed ID: 14649387
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular issues of COX-2 inhibitors and NSAIDs.
Wong M; Chowienczyk P; Kirkham B
Aust Fam Physician; 2005 Nov; 34(11):945-8. PubMed ID: 16299629
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance.
Borer JS; Simon LS
Arthritis Res Ther; 2005; 7 Suppl 4(Suppl 4):S14-22. PubMed ID: 16168077
[TBL] [Abstract][Full Text] [Related]
6. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis.
Gunter BR; Butler KA; Wallace RL; Smith SM; Harirforoosh S
J Clin Pharm Ther; 2017 Feb; 42(1):27-38. PubMed ID: 28019014
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
[TBL] [Abstract][Full Text] [Related]
8. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?
Strand V
Lancet; 2007 Dec; 370(9605):2138-51. PubMed ID: 18156036
[TBL] [Abstract][Full Text] [Related]
9. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke.
Haag MD; Bos MJ; Hofman A; Koudstaal PJ; Breteler MM; Stricker BH
Arch Intern Med; 2008 Jun; 168(11):1219-24. PubMed ID: 18541831
[TBL] [Abstract][Full Text] [Related]
10. Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs.
Maillard M; Burnier M
Expert Opin Drug Saf; 2006 Jan; 5(1):83-94. PubMed ID: 16370958
[TBL] [Abstract][Full Text] [Related]
11. [Nonsteroidal antiinflammatory drugs: gastrointestinal and cardiovascular and renal safety].
Oscanoa-Espinoza T; Lizaraso-Soto F
Rev Gastroenterol Peru; 2015 Jan; 35(1):63-71. PubMed ID: 25875519
[TBL] [Abstract][Full Text] [Related]
12. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
Hochberg MC
Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular Safety and Bleeding Risk Associated with Nonsteroidal Anti-Inflammatory Medications in Patients with Cardiovascular Disease.
Ross SJ; Elgendy IY; Bavry AA
Curr Cardiol Rep; 2017 Jan; 19(1):8. PubMed ID: 28138824
[TBL] [Abstract][Full Text] [Related]
14. Cyclo-oxygenase-2 inhibitors: when should they be used in the elderly?
Savage R
Drugs Aging; 2005; 22(3):185-200. PubMed ID: 15813652
[TBL] [Abstract][Full Text] [Related]
15. FDA labeling of NSAIDs: Review of nonsteroidal anti-inflammatory drugs in cardiovascular disease.
Pirlamarla P; Bond RM
Trends Cardiovasc Med; 2016 Nov; 26(8):675-680. PubMed ID: 27238053
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular risk, hypertension, and NSAIDs.
White WB
Curr Rheumatol Rep; 2007 Apr; 9(1):36-43. PubMed ID: 17437665
[TBL] [Abstract][Full Text] [Related]
17. Cyclooxygenase-2 inhibitors: are they really atherothrombotic, and if not, why not?
Hankey GJ; Eikelboom JW
Stroke; 2003 Nov; 34(11):2736-40. PubMed ID: 14576372
[TBL] [Abstract][Full Text] [Related]
18. An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I.
Moyad MA
Semin Urol Oncol; 2001 Nov; 19(4):294-305. PubMed ID: 11769881
[TBL] [Abstract][Full Text] [Related]
19. [Nonsteroidal anti-inflammatory drugs and the risk of cardiovascular diseases].
Jukić A; Kaliterna DM; Radić M
Reumatizam; 2010; 57(1):26-8. PubMed ID: 20941937
[TBL] [Abstract][Full Text] [Related]
20. Nonsteroidal anti-inflammatory drugs and cardiovascular safety - translating pharmacological data into clinical readouts.
Tacconelli S; Bruno A; Grande R; Ballerini P; Patrignani P
Expert Opin Drug Saf; 2017 Jul; 16(7):791-807. PubMed ID: 28569569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
